Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Saved in:
Bibliographic Details
Title: Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.
Authors: Jang HJ; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI.; Department of Cell Biology, Van Andel Institute, Grand Rapids, MI., Urrutia G; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Ørskov AD; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Biotech Research & Innovation Center, University of Copenhagen, Copenhagen, Denmark., Nguyen AV; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Kim HJ; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Nelson SA; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Lee H; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Burgos RS; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Johnson BK; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., Wegener M; Genomics Core, Van Andel Institute, Grand Rapids, MI., Becker K; Genomics Core, Van Andel Institute, Grand Rapids, MI., Adams M; Genomics Core, Van Andel Institute, Grand Rapids, MI., Sheridan R; Flow Cytometry Core, Van Andel Institute, Grand Rapids, MI., Ramjan ZH; Bioinformatics and Biostatistics Core, Van Andel Institute, Grand Rapids, MI., Givan SA; Bioinformatics and Biostatistics Core, Van Andel Institute, Grand Rapids, MI., Zebley CC; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN.; Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN., Youngblood BA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN., Issa JJ; Coriell Institute for Medical Research, Camden, NJ., Topper MJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD., Baylin SB; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD., Baer MR; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD., Triche TJ Jr; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI., O'Connell CL; Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA., Grønbæk K; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Biotech Research & Innovation Center, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Jones PA; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI.
Source: Blood neoplasia [Blood Neoplasia] 2026 May 05; Vol. 3 (3), pp. 100243. Date of Electronic Publication: 2026 May 05 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2950-3280
DOI:10.1016/j.bneo.2026.100243